Long-Term SWOG Trial Data Suggest Cure Possible in Advanced Follicular Lymphoma
Key Clinical Summary
- In the SWOG S0016 trial, 15-year follow-up showed a 40% progression-free survival (PFS) and 70% overall survival (OS) in advanced-stage follicular lymphoma (FL).
- Cure modeling estimated that 42% of patients achieved cure after first-line CHOP-based chemoimmunotherapy.
- Relapse rates declined markedly over time, falling from 6.8% in the first 5 years to 0.6% between years 15 and 20.
Follicular lymphoma (FL) has long been considered incurable due to late relapses after initial therapy. However, a 15-year follow-up analysis of the SWOG S0016 randomized clinical trial challenges this paradigm, suggesting that a substantial subset of patients with advanced-stage FL may achieve cure after frontline CHOP-based chemoimmunotherapy.
Study Findings
SWOG S0016 was a multicenter, intergroup phase 3 trial conducted across academic and community centers in the US. Between May 2001 and October 2008, 531 eligible patients with previously untreated, advanced-stage FL were enrolled and randomized to rituximab plus CHOP (R-CHOP; n = 267) or CHOP followed by iodine-131–tositumomab radioimmunotherapy (CHOP-RIT; n = 264). Median follow-up reached 15.5 years (IQR, 13.6-16.9).
At 15 years, OS was 70%, with no significant difference between treatment arms. The overall 15-year PFS was 40% (95% CI, 36.0% to 44.7%). CHOP-RIT was associated with superior 15-year PFS compared with R-CHOP (47% vs 34%; P = .004).
Using a relative survival–based cure model that accounted for background mortality, investigators estimated an overall cure rate of 42%, including 35% among patients treated with R-CHOP. Cure rates were highest in patients with low Follicular Lymphoma International Prognostic Index (FLIPI) scores and normal β2-microglobulin levels.
Importantly, relapse rates decreased substantially over time, from 6.8% in the first 5 years to just 0.6% between years 15 and 20. Fewer than half of observed deaths were lymphoma-related, helping explain why the estimated cured fraction exceeded the 15-year PFS rate.
Clinical Implications
These long-term data challenge the long-held view that advanced-stage FL is universally incurable. The finding that 42% of patients may be cured with a single course of induction chemoimmunotherapy—without maintenance rituximab—represents a potential paradigm shift in first-line management.
The results also have implications for survivorship care. Given the sharp decline in late relapse risk and the plateauing of lymphoma-related events, indefinite oncology and radiologic follow-up may not be necessary for all patients. Transitioning long-term survivors to primary care after 10 years could be considered.
For clinical trial design, CHOP-based chemoimmunotherapy remains a benchmark and standard of care in the first-line setting. While novel nonchemotherapy regimens are under investigation, particularly for patients with comorbidities, these data reinforce the curative potential of established chemoimmunotherapy—especially in patients with favorable prognostic markers.
The investigators noted that their findings provide “the strongest evidence to date that a cure is achievable for a subset of patients with advanced-stage disease after standard frontline chemoimmunotherapy.” They emphasized that cure was defined as having “no chance of lymphoma recurrence during a patient’s expected lifespan,” and that late relapses observed were consistent with the presence of a smaller uncured subpopulation rather than evidence against curability.
Conclusion
With more than 15 years of follow-up, the SWOG S0016 analysis suggests that cure is achievable in a substantial proportion of patients with advanced-stage FL treated with CHOP-based chemoimmunotherapy. These findings may reshape patient counseling, long-term follow-up strategies, and future research in FL.
Reference
Shadman M, LeBlanc M, Rimsza L, et al. Treatment of follicular lymphoma with CHOP and anti-CD20 therapy15-year follow-up of the SWOG S0016 trial. JAMA Oncol. 2026. doi: 10.1001/jamaoncol.2026.0042
